Dr Reddy’s (NSE: DRREDDY) Shares Tumble 7% After Semaglutide Launch Delay Due to API Quality Issue

Dr Reddy’s Laboratories shares tumbled nearly 7% on Thursday, July 9, 2026, on the NSE. The Hyderabad-based drugmaker disclosed a quality issue affecting its semaglutide active pharmaceutical ingredient. Certain batches were found out of specification, delaying commercial supplies indefinitely. Shares fell as much as 6.5% to an intraday low of ₹1,261.20 on the BSE. That marks an 11% correction from the stock’s 52-week high of ₹1,414.40. Dr Reddy’s says the issue carries no patient safety or regulatory filing impact.

Why Dr Reddy’s Shares Fell Sharply Today

Dr Reddy’s (DRREDDY.NS) informed stock exchanges Thursday that semaglutide batches showed API-related quality deviations. The company said it is investigating the root cause behind this manufacturing issue. Commercial supplies will remain delayed until the investigation concludes, with no timeline specified yet.

Shares dropped to ₹1,261.20 intraday, down roughly 6.5% from Wednesday’s close. By 11:29 AM, the stock traded 5% lower at ₹1,279 per share. That decline stood out sharply against the BSE Sensex, which gained 0.86% during the same session.

What Dr Reddy’s Said About Patient Safety

Dr Reddy’s clarified that this API issue does not affect patient safety in any way. The company also confirmed its existing global regulatory filings remain fully unaffected by this delay. Management said it remains committed to ensuring reliable global supplies of this therapy.

Dr Reddy’s will host an investor conference call later Thursday to address the situation directly. That call aims to answer analyst and shareholder questions about the delay’s business impact.

#WATCH | Why has Dr Reddy's flagged a delay in semaglutide supplies?

Dr Reddy's says supplies have been delayed due to an API quality issue. The company clarified that there is no impact on patient safety or existing regulatory approvals, and that corrective measures are… pic.twitter.com/beiOXURN8C

— ET NOW (@ETNOWlive) July 9, 2026

Dr Reddy’s Semaglutide Business Context

Dr Reddy’s became the first company to secure generic semaglutide market authorization in India and Canada. It launched an oral semaglutide biosimilar under the Obeda brand in India during May 2026. That product targets Type 2 diabetes patients as part of the company’s expanding GLP-1 portfolio.

Semaglutide represents Dr Reddy’s near-term opportunity within the fast-growing GLP-1 therapy category globally. Patent expiries across Canada, India, Brazil, Turkey, and China are opening pathways for lower-cost competitors. Rivals Sun Pharmaceutical, Cipla, Lupin, Biocon, and Zydus Lifesciences are all pursuing similar semaglutide opportunities.

How Big Is The GLP-1 Opportunity

Global GLP-1 therapies are projected to grow at a 20% compound annual rate through 2030. By then, these drugs could account for nearly 9% of global prescription drug sales. Five of the ten best-selling medicines worldwide are expected to be GLP-1 therapies by 2030.

Management has guided toward 6 to 7 million semaglutide pen sales during calendar year 2026. This delay introduces near-term uncertainty around whether that specific volume target remains achievable now.

Analyst Reactions To The Delay

Emkay Global Financial Services flagged ongoing pricing pressure within Dr Reddy’s core US base business. The brokerage noted gross margins showed clear strain during the March 2026 quarter results. Analysts said the June 2026 quarter will reveal whether current US revenue trends hold steady.

Choice Institutional Equities maintained a positive stance, describing Q4 FY26 headwinds as largely one-off events. The brokerage continues expecting strong growth visibility as Dr Reddy’s semaglutide and biosimilar businesses scale further. Management has separately guided toward gross margin recovery above 50% during FY27.

Dr Reddy’s Broader Stock Performance

Dr Reddy’s has still outperformed the broader market over the past six months despite today’s drop. The stock gained 6% during that period, while the BSE Sensex declined 8%. The BSE Healthcare Index rallied 14% over the same six-month stretch, outpacing Dr Reddy’s individually.

This context suggests today’s selloff reflects a specific operational setback, not a sector-wide healthcare downturn. Investors will likely watch for updates on the API investigation before reassessing the stock further.

Final Thoughts

Dr Reddy’s semaglutide delay triggered a sharp near-7% share price decline despite no patient safety concerns. The API quality issue adds fresh uncertainty to an otherwise promising GLP-1 growth story for the company. Analyst views remain mixed, balancing near-term margin pressure against long-term semaglutide market potential. Investors tracking Dr Reddy’s alongside peers like Sun Pharmaceutical and Cipla should watch for the root-cause investigation update.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.